Cargando…

A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug

BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogari, Neda M., Aljohani, Ashwag, Amin, Amr A., Al-Allaf, Faisal A., Dannoun, Anas, Taher, Mohiuddin M., Elsayed, Atalla, Rednah, Dareen ibrahim, Elkhatee, Osama, Porqueddu, Massimo, Alamanni, Francesco, Khogeer, Soud Abdulraof A., Fawzy, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318928/
https://www.ncbi.nlm.nih.gov/pubmed/30606120
http://dx.doi.org/10.1186/s12872-018-0965-3
_version_ 1783384973664845824
author Bogari, Neda M.
Aljohani, Ashwag
Amin, Amr A.
Al-Allaf, Faisal A.
Dannoun, Anas
Taher, Mohiuddin M.
Elsayed, Atalla
Rednah, Dareen ibrahim
Elkhatee, Osama
Porqueddu, Massimo
Alamanni, Francesco
Khogeer, Soud Abdulraof A.
Fawzy, Ahmed
author_facet Bogari, Neda M.
Aljohani, Ashwag
Amin, Amr A.
Al-Allaf, Faisal A.
Dannoun, Anas
Taher, Mohiuddin M.
Elsayed, Atalla
Rednah, Dareen ibrahim
Elkhatee, Osama
Porqueddu, Massimo
Alamanni, Francesco
Khogeer, Soud Abdulraof A.
Fawzy, Ahmed
author_sort Bogari, Neda M.
collection PubMed
description BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug. METHODS: We here report that a recently identified genetic variant, c.553G > T in the APOA5 gene which causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated with increased TG levels. To investigate theses effects, a case-control study compressing 608 subjects from the same area was performed. RESULTS: TG levels in T allele patients were significantly lower than the control GT allele patient (χ(2) = 2.382E2(a), P-value < 0.001). Overall, patients carrying T allele showed lower levels of TG than patients carrying GG allele. The homozygous patient for the T allele presented normal cholesterol levels of 134 mg/dl, and the levels in GG patients ranged from 25 to 340 mg/dl (P-value < 0.001). In summary, we demonstrated that the presence of c.553G > T variant (rs2075291); in APOA5 gene increases human plasma TG levels. CONCLUSION: Nevertheless, T allele is found to reduce TG levels in CAD patients who are on the cholesterol medication, atorvastatin. Thus, c.553G > T variant can be considered as a significant predicator of hypertriglyceridemia. In addition, it could be used as a hallmark for the diagnosis and prognosis of CAD.
format Online
Article
Text
id pubmed-6318928
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63189282019-01-08 A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug Bogari, Neda M. Aljohani, Ashwag Amin, Amr A. Al-Allaf, Faisal A. Dannoun, Anas Taher, Mohiuddin M. Elsayed, Atalla Rednah, Dareen ibrahim Elkhatee, Osama Porqueddu, Massimo Alamanni, Francesco Khogeer, Soud Abdulraof A. Fawzy, Ahmed BMC Cardiovasc Disord Research Article BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug. METHODS: We here report that a recently identified genetic variant, c.553G > T in the APOA5 gene which causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated with increased TG levels. To investigate theses effects, a case-control study compressing 608 subjects from the same area was performed. RESULTS: TG levels in T allele patients were significantly lower than the control GT allele patient (χ(2) = 2.382E2(a), P-value < 0.001). Overall, patients carrying T allele showed lower levels of TG than patients carrying GG allele. The homozygous patient for the T allele presented normal cholesterol levels of 134 mg/dl, and the levels in GG patients ranged from 25 to 340 mg/dl (P-value < 0.001). In summary, we demonstrated that the presence of c.553G > T variant (rs2075291); in APOA5 gene increases human plasma TG levels. CONCLUSION: Nevertheless, T allele is found to reduce TG levels in CAD patients who are on the cholesterol medication, atorvastatin. Thus, c.553G > T variant can be considered as a significant predicator of hypertriglyceridemia. In addition, it could be used as a hallmark for the diagnosis and prognosis of CAD. BioMed Central 2019-01-03 /pmc/articles/PMC6318928/ /pubmed/30606120 http://dx.doi.org/10.1186/s12872-018-0965-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bogari, Neda M.
Aljohani, Ashwag
Amin, Amr A.
Al-Allaf, Faisal A.
Dannoun, Anas
Taher, Mohiuddin M.
Elsayed, Atalla
Rednah, Dareen ibrahim
Elkhatee, Osama
Porqueddu, Massimo
Alamanni, Francesco
Khogeer, Soud Abdulraof A.
Fawzy, Ahmed
A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
title A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
title_full A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
title_fullStr A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
title_full_unstemmed A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
title_short A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
title_sort genetic variant c.553g > t (rs2075291) in the apolipoprotein a5 gene is associated with altered triglycerides levels in coronary artery disease (cad) patients with lipid lowering drug
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318928/
https://www.ncbi.nlm.nih.gov/pubmed/30606120
http://dx.doi.org/10.1186/s12872-018-0965-3
work_keys_str_mv AT bogarinedam ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT aljohaniashwag ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT aminamra ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT alallaffaisala ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT dannounanas ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT tahermohiuddinm ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT elsayedatalla ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT rednahdareenibrahim ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT elkhateeosama ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT porqueddumassimo ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT alamannifrancesco ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT khogeersoudabdulraofa ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT fawzyahmed ageneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT bogarinedam geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT aljohaniashwag geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT aminamra geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT alallaffaisala geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT dannounanas geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT tahermohiuddinm geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT elsayedatalla geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT rednahdareenibrahim geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT elkhateeosama geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT porqueddumassimo geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT alamannifrancesco geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT khogeersoudabdulraofa geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug
AT fawzyahmed geneticvariantc553gtrs2075291intheapolipoproteina5geneisassociatedwithalteredtriglycerideslevelsincoronaryarterydiseasecadpatientswithlipidloweringdrug